Brazilian pharmaceutical firm Precisa Medicamentos is about to ask Brazilian health regulator (Anvisa) for authorization to carry out phase 3 clinical trials in Brazil from Covaxin, the COVID-19 vaccine developed by the Indian laboratory Bharat Biotech, says G1. This vaccine could add up CoronaVac and AstraZeneca’s doses in the country.

These trials are one of the requirements for the emergency use approval of the immunizer by Anvisa. So far, India approved the use of Covaxin only with the results of phases 1 and 2 of trials, which does not meet Anvisa’s requirements.

Covaxin is also the vaccine that is on the plans of Brazilian private clinics, besides the attempt from AstraZeneca.